

Resource Summary Report

Generated by RRID on Aug 1, 2026

FITC anti-human CD44

RRID:AB_1501197

Type: Antibody

Proper Citation

BioLegend Cat# 338804, RRID:AB_1501197

Antibody Information

URL: http://antibodyregistry.org/AB_1501197

Proper Citation: BioLegend Cat# 338804, RRID:AB_1501197

Target Antigen: CD44

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD44

Description: This monoclonal targets CD44

Target Organism: human

Clone ID: Clone BJ18

Antibody ID: AB_1501197

Vendor: BioLegend

Catalog Number: 338804

Alternative Catalog Numbers: 338803

Record Creation Time: 20250820T054418+0000

Record Last Update: 20250820T222057+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD44.

No alerts have been found for FITC anti-human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Danielli SG, et al. (2024) Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. *Molecular cancer therapeutics*, 23(6), 864.

Wang R, et al. (2023) A human skeletal muscle stem/myotube model reveals multiple signaling targets of cancer secretome in skeletal muscle. *iScience*, 26(4), 106541.

Ma Z, et al. (2022) Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. *Cancer cell*, 40(12), 1550.

Ayhan S, et al. (2021) Characterization of human bone marrow niches with metabolome and transcriptome profiling. *Journal of cell science*, 134(6).